#cannabisaficionado

Cannabis

Celebrate 710 with the Aficionado Guide to Cannabis Concentrates

Published

on

White Apricot Sherbet. PHOTO | Oleum Extracts
Advertisement Back2Grow Advertisement

For many enthusiasts, concentrates are among the most enjoyable and versatile of cannabis products. While a little concentrate goes a long way, these extracts are easily vaporized, smoked, or used to make infused topicals, edibles, and more. Not all concentrates, however, are created equal. The way that different cannabis concentrates are prepared has an impact on the end result. 

In order to delve deeper into the past, present and future of cannabis concentrates this 710, we have called in the expertise of the team from Oleum Extracts. The Washington-based, multi-award-winning processor company is considered to be one of the best in the industry, developing consistently innovative products — like their THCA crystalline Wizard Stones — and producing high-quality extracts.

Here’s what every aficionado needs to know about cannabis concentrates.  

The Evolution of Cannabis Concentrates

PHOTO | Oleum Extracts

Oleum Extracts believe that the evolution of cannabis concentrates has seen a shift away from the wants and needs of producers towards those of the consumers.

“As consumers become more educated, they are asking better and more meaningful questions regarding the products they are ingesting/consuming, which is a good thing,” said Team Oleum. “New topics such as cannabinoid profiles, terpene profiles, how the products made, what kind of materials are used, and knowledge of the manufacturers are making their way into the purchasing decisions of consumers.”

They also think that as consumers become savvier to which companies and products have the most stringent production policies and consistent products, “brand trust and loyalty are beginning to make their presence felt.”

When purchasing cannabis concentrates, asking for the cheapest products with the highest THC levels should not be at the forefront of consumers minds and Team Oleum believes “we’re starting to see this shift happen away from that type of thinking.”

Recent developments of isolation products demonstrate “the evolution of concentrates that can be seen in THCA, THCV (appetite suppressant), CBD, CBG, CBN (sleep aid) and Delta-8-THC (anti-nausea).”

Oleum’s THCA Crystalline Wizard Stones are a good example of this. They pride themselves in the purity of their extracts, and test results of the Wizard Stones “often come back at 99.8%+ pure,” they said.

“We are anxious to see what comes out of the isolation of these other cannabinoids, as these compounds are often only found in trace amounts in flower form (less than 1%). Now that we are able to isolate them, we will be able to see the implications of larger doses and combinations of these cannabinoids and/or cannabis-derived terpenes on the human vessel.”

All About Solvents

The majority of cannabis concentrates require a solvent to extract. A solvent is a substance, usually a liquid or a gas, that separates trichome resin glands from unwanted plant material. The separated essential oil is then collected and further processed to create the high-potency oils and products that are so popular today.

Many different solvents can be used to make cannabis concentrates. Of these, however, there are three solvents that dominate the market: butane, carbon dioxide, and ethanol. Each of these solvents is used to effectively remove cannabis resin from the plant and concentrate the resin into the sap-like oil aficionado’s everywhere have come to know and love.

Butane

Butane is one of the cheapest solvents to use when making cannabis concentrates. It was also the first solvent to be used to make concentrates for dabbing, and concentrates made with this solvent are often referred to as butane hash oil (BHO). In general, concentrates extracted with butane tend to preserve more aromatic qualities than those extracted with carbon dioxide. For this reason, butane is used to make live resin, a concentrate rich in aromatic molecules called terpenes. No other solvent can be used to make live resin.

Carbon Dioxide

Carbon dioxide (CO2) is most commonly used to make syrupy extracts for vapor pens. The solvent, however, can also be used to make other forms of concentrates. Oils extracted with carbon dioxide can be dabbed, used to fill capsules, or used as oils put underneath the tongue. Unlike butane, however, carbon dioxide tends to remove much of the terpene aroma molecules found in cannabis flower. As such, CO2 oil can feature a strikingly different chemical composition than the cannabis plant from which it came.

Ethanol

Concentrates extracted with ethanol are among the most expensive around. And yet, this solvent is perhaps one of the best to use during cannabis extractions. For those hoping to maintain aromatic terpenes in their concentrate, products made with ethanol are typically the way to go. Ethanol captures more terpenes and pigment molecules called flavonoids than other concentrates. Concentrates made with ethanol are sometimes processed into full spectrum cannabis oil (FECO), while others are used to make products for dabbing.

How To Spot Quality Concentrates

PHOTO | Oleum Extracts

Searching for truly high-quality material? There are three basic factors to keep in mind: color, consistency, and lab reports. A hallmark sign of quality in almost all cannabis concentrates is a golden-amber coloration. Most solvent-based concentrates should appear amber, although the color can range a light gold to warm rust.

Some concentrates, like FECO and RSO, may look almost black. The deep coloration in these products indicates that greater amounts of chlorophyll were extracted along with other cannabis compounds. While more chlorophyll may provide a bitter, herbal taste, the inclusion of a greater variety of plant chemicals may make these types of concentrates more appealing to medical consumers.

The introduction of alternative methods and new equipment has resulted in an improvement in cannabis concentrates — good news for the aforementioned medical patients and dabbing enthusiasts alike.

“Equipment manufacturer’s from other industries are now tailoring their businesses to accommodate cannabism, which has been a great thing to experience,” said Team Oleum. “I’m sure we will continue to see this trend moving forward, especially as extraction and processing evolve to service high volume needs as the market expands.”

Concentrates should feature a fairly consistent constitution. No one, for example, wants to find hard chunks in their budder, nor do they want to find leaf matter or stem fragments in their hash. If a concentrate doesn’t take on the form that is advertised, chances are it is a low-quality product.

“In the beginning, good concentrates were known pretty much by aesthetics and the way they looked,” said Team Oleum. “Followed up with a sniff, the color and smell of the product were the easiest ways to spot a good concentrate back in the day. Now, a concentrate can look great, and even smell ok, but once dabbed or vaped might taste horrendous.”

Team Oleum believe that regulations and laws in Washington’s market are making people purchase products on looks, rather than smell.

“With the legal market here in WA, the consumer is not allowed to open the package of concentrate or smell the product before purchasing,” said Team Oleum. “This takes away what beforehand was a vital component in making a decision of what product to buy and how much to purchase. As a result, it seems to be aesthetics and brand trust that leads most in their decisions today in spotting good concentrates.”

Third-party lab reports are essential, proving the manufacturer and consumer with information on the chemical constituents in the concentrate, like the terpene profiles of the flower.

“While a concentrate may look attractive, low-quality flower with low terpene content may have been used during the extraction,” said Team Oleum. “Most lab reports list information on the potency and dominant cannabinoids in the product. Some reports, however, will also list the primary terpenes in the concentrate as well. In general, the more terpenes preserved in the concentrate, the greater the flavor and aroma.”

“The only individuals really doing any quality control of the products before going out to market are the producers and processors themselves. If these individuals are not cannabis consumers,  and/or are not trying their own products it is doing a great disservice to both their brand and their consumers.

“If the owners and operators of these brands do a good enough job at this, the reward is consumer trust in both the brand and its products. When people can trust where the material is being sourced, how it is being processed and the care that goes into its production from start to finish. These are the brands that are earning the most market share and seeing the most positive feedback from consumers.”

Most Common Concentrate Preparations

Walk into any cannabis shop these days and you’re sure to find a plethora of containers filled with sticky goo. The market for cannabis concentrates is growing faster than ever, with data suggesting that concentrate sales may surpass sales for dry flower within the next four years. Here are some of the most popular cannabis concentrate products — including some specialties from Oleum Extracts.

Shatter

Cannabis Concentrates

PHOTO | RuggedCoast

Shatter is easy to spot in a dispensary but relatively difficult to make for extractors. Shatter is a cannabis concentrate that takes on the consistency of an amber-colored glass shard. These shards can be broken up and dabbed, although the oil’s crystalline constitution makes it slightly more difficult to work with than other concentrate preparations.

Wax

PHOTO | David

Wax and shatter are made in essentially the same way, although wax tends to be physically agitated more during processing. As a result, the preparation loses its glass-like consistency and instead develops a waxy, honeycomb-like constitution. Some individual strains may also be more inclined to “wax up” than other strains. In general, waxes tend to be softer and easier to manipulate than shatters.

Budder

Budder is whipped wax. Instead of walking on eggshells trying to create a glass-like shatter, budder is whipped automatically in order to create a smoothe yet opaque concentrate. The end result is soft, fluffy, and easy to manipulate.

Oil

PHOTO | Eric Limon

Cannabis oils are concentrates that maintain a consistent liquid state. Oils are most often made with ethanol, which preserves the widest array of phytochemicals found in any cannabis extraction. Oils of this type are often referred to as full-spectrum cannabis oil (FECO) or Rick Simpson Oil (RSO). These oils are often used under the tongue or are ingested orally. Carbon dioxide, however, can also be used to make a syrupy oil, such as that found in vapor cartridges.

Live Resin

PHOTO | Oleum Extracts

Live resin is a king among concentrates. Unlike all other concentrates, live resin is made using fresh cannabis flowers that have been flash-frozen in order to preserve terpene quality. These fresh flowers are then processed using butane as a solvent, creating a wet and semi-solid concentrate that features superior flavor, aroma, and overall terpene quality.
Solventless Concentrates

Using a solvent is the easiest way to extract cannabis concentrates. Solvents, however, are not required to make a concentrated cannabis product. Products like hash and rosin do not require solvents at all, which makes them preferable to many consumers. Although, solventless concentrates tend to be less potent than their solvent-based counterparts.

Rocks and Sauce: Oleum Extracts

Cannabis Concentrates

PHOTO | Oleum Extracts

“Rocks and Sauce is a product where THCA crystals grow in their own high terpene extraction,” said Team Oleum. “They are often made from fresh frozen material but can be made from dried/cured material, too.”

Honey Crystal/CryoTek: Oleum Extracts

Cannabis Concentrates

PHOTO | Oleum Extracts

“This product is fully dewaxed, quad filtered and highly processed,” said Team Oleum. “We make Honey Crystal/CryoTek from dried/cured material. CryoTek means that the Honey Crystal has gone through an additional stage of processing to further refine the material.”

Hash

PHOTO | Frenchy Cannoli

Hash is one of the oldest cannabis preparations available. It’s also one of the simplest to make. Hash is most often made by rubbing dried cannabis flower on a screen, breaking off trichomes via agitation. The broken trichomes are then collected and compressed into hash.

Bubble hash or ice water hash is another type of concentrate made using agitation. Only, this variety of hash uses ice water to freeze trichome resin glands. The cold temperature makes trichomes more brittle, which allows them to more easily break away from plant material. The end result is grainy trichome goo that is then dried and compressed into hash.

Rosin

Cannabis Concentrates

PHOTO | RuggedCoast

Rosin is one of the most popular concentrates available today. Like hash, rosin is relatively easy to make. This solventless preparation uses heat and pressure to melt trichomes off of plant material. These trichomes are often melted between two solid hot plates, which compresses them into an almost shatter-like consistency. Rosin tends to be slightly translucent, although it remains mailable and soft, a stark contrast to shatter’s glass-like nature.

Terpsoline: Oleum Extracts

Cannabis Concentrates

Photo | Oleum Extracts

“Terpsoline is another one of our products that is made of up of THCA Crystalline Wizard Stones and cannabis-derived terpenes,” said Team Oleum.

Exciting Advances and New Developments in the World of Cannabis Concentrates

Cannabis Concentrates

PHOTO | Oleum Extracts

Team Oleum believe that isolates, the separation of cannabinoids and terpenes are exciting developments and new in the field of concentrates.

“We are now starting to understand isolation and separation on a much deeper level,” said Team Oleum. “This allows us to reconfigure ratios of cannabinoids to terpenes — to alter the experience, flavors and effects of these products.

“This has never been an option before with cannabis concentrates, we believe the future will incorporate a lot of these unique and novel combinations into the cannabis consumer’s diet. For instance, our IceWalker is a product that incorporates THCA Crystalline Wizard Stones, Delta-8-AquaTek Distillate and cannabis-derived terpenes. These types of concentrate concoctions were not possible a few years ago, we are excited to see what will come available in the next five years.

“In addition to isolations, we are also starting to retain terpenes (flavors) and their respective cannabinoids in such a way as to mimic the actual taste, smell and effect of the flower it comes from. It wasn’t too long ago that material was just put into a column and blasted with solvent, hoping for the best outcome in the end product and it was often hit or miss. Now, a lot more science, better cultivation, and preparation of materials, and better understanding and innovation of equipment have allowed us to employ much more efficient methods in cannabis extraction and processing. This, in turn, allows us to produce a much higher quality product much more consistently. Something that benefits both the producers and the consumers.

“Last but not least, CRC (Color Remediation Cartridge) seems to be making an introduction by offering solutions to the removal of unwanted colors and compounds in cannabis concentrates. These colors and compounds include lipids, chlorophyll, carotene, xanthophyll, pheophytins and lycopene,” said Team Oleum. “Due to the compounds being used in this process, it should only be done by those with proper equipment/lab and training. It definitely has its place in the concentrate industry as a means of cleaning up product, but in the same breath, good concentrates should always come from good starting material. As the tried and true saying goes, “Fire In.. Fire Out”.

“These methods of remediation can often take away from the true and original character of the strain and extract. We try to stay as close to the original cultivar as we can…in most cases it’s what we and the end consumer prefers.”

Cannabis

Israel’s Cannabis Trade Probe Moves Toward a Four-Producer Review

Israel’s latest procedural step puts four Canadian producers in focus, while the distinction between an investigation and an imposed trade duty remains essential.

Published

on

Shipping containers and cranes at a commercial port

Israel’s investigation of Canadian medical cannabis imports has reached another procedural stage, with four producers identified for closer examination, according to reporting on an October 22 notice. The development concerns how investigators will assess exporters. It does not, by itself, establish that dumping occurred or impose a new import duty.

Israel’s Cannabis Magazine reported that the trade-levies commissioner selected Koots Canna, 2323414 Alberta and Cielo Verde Quebec as a sample, with GrowCo to be examined separately. The outlet said it obtained the commissioner’s document. Cannabis Aficionado has reviewed the published reporting, rather than independently obtained that notice.

Why four producers are in focus

According to Cannabis Magazine, the three sampled growers represent about 22 percent of exports among the 16 indoor and hybrid growers that supplied data. GrowCo was singled out because of its greenhouse production and export volume. The report says the four together cover approximately 70 percent of Canadian cannabis imports into Israel during the relevant investigation period.

Those are descriptions of the proposed examination, not market-share figures that should automatically be applied to current retail sales. The reporting also describes a five-business-day response period for parties to comment. A reader should not mistake that opportunity to respond for a final ruling.

StratCann’s October 23 report adds that 22 Canadian companies supplied initial responses and 17 had exported during the investigation period. Its account says the commissioner considered individual calculations for every cooperating exporter impractical within the available time. Sampling is therefore central to this stage of the dispute.

What “dumping” means in this context

The World Trade Organization’s explanation of anti-dumping rules describes dumping as exports sold below their normal value, generally assessed against the exporting market. It is a trade-law pricing question. It is not an allegation that cannabis was contaminated, illegally cultivated or unsuitable for patients.

The comparison is more involved than placing two advertised prices side by side. The WTO describes adjustments that can be needed for differences in sale conditions, quantities, taxation and product characteristics. Its framework also requires consideration of material injury to a domestic industry and a causal link between that injury and dumped imports.

That makes production methods and comparable pricing relevant without making either conclusive. A greenhouse producer can have different costs from an indoor grower, but a cost difference alone does not settle all the questions required for an anti-dumping measure. The investigation has to establish the relevant facts through its process.

A dispute with several procedural turns

The latest review follows an earlier investigation that was closed in July. In a July 28 notice, Israel’s Ministry of Economy and Industry said the closure was for procedural reasons: advance notification had not been provided to the exporting country’s competent authority because of human error.

The ministry explicitly said that closure was not a substantive determination on the complaint. It also preserved the possibility of a further complaint or a new investigation. The distinction matters in both directions: closure did not establish that the allegations were correct, and it did not establish that they were disproven.

Cronos Group’s securities filing records a new complaint dated July 30, notification to Canada on August 2 and notice to the company on August 5 that a new investigation had begun. The company says it cannot predict the outcome or whether provisional or final duties will ultimately be imposed.

The filing also traces the earlier case to January 2024 and describes the finance minister’s opposition to the proposed duty in April 2025. It records subsequent court challenges as well. That history helps explain why earlier proposed tariff percentages should not be presented as the rate established by the October 2026 sample-selection step.

What changes for readers and businesses now

For businesses, the immediate development is a more specific picture of which exporters may receive detailed scrutiny. It is not enough information to calculate a new landed cost, predict a supplier’s future prices or announce an interruption to patient supply. Those claims would require additional evidence.

For patients and other readers, an investigation headline should remain separate from a product-safety headline. Nothing in this procedural selection establishes a health finding about a named producer’s cannabis. Nor does it establish a new prescription rule.

The next substantive items to watch are the commissioner’s treatment of responses to the sample, any published preliminary determination and any resulting measure. Reports available for this article describe sample selection, with no preliminary duty decision reported at that stage. Until a later document changes that position, the appropriate description is an unresolved trade investigation.

Illustrative stock trade photograph; not a documented cannabis shipment or an Israeli port. Photo: Andrea Musto / Pexels.

Continue Reading

Cannabis

New Zealand Cannabis Trial Takes a Longer Look at Sleep and Back Pain

A small University of Auckland study will compare a cannabis oil with placebo over months, separating an important research question from claims of proven benefit.

Published

on

Woman resting on a white pillow in a bedroom

Can a cannabis medicine improve sleep for people living with chronic back pain over several months? A University of Auckland study is examining that question, with a recent update from medicine supplier Helius drawing attention to an ongoing trial that has yet to report results.

The CPS trial is designed to compare a THC–CBD oil with placebo in approximately 20 adults. Its value lies in the comparison and the follow-up period: the research asks whether improvements hold up beyond an initial experience with a product, rather than treating a personal account of better sleep as proof.

An ongoing study, not a new treatment finding

In its October update, Helius describes a randomized, double-blind, placebo-controlled crossover trial. Participants are to receive the medicine for three months and placebo for three months, in a randomly assigned order. The company says it provides the study products but has no role in conducting the research, analyzing the data or reporting the findings.

Helius expects results in early 2028. That is a projected reporting window, not a completed result or a promise that the product will work. The announcement should also be distinguished from the trial’s start: the registry records a first participant enrollment date in October 2025.

What the researchers will measure

The Australian New Zealand Clinical Trials Registry entry identifies change in the Insomnia Severity Index as the primary outcome. Additional measures include pain scores and wrist-monitor estimates of total sleep time, time awake after falling asleep, sleep efficiency and the time taken to fall asleep.

Those measures address related but different experiences. Feeling that sleep has improved, spending longer asleep and reporting less pain are not interchangeable outcomes. Looking at them together can provide a more useful picture than a single headline about cannabis and sleep.

The registered design also includes a washout period between treatment phases. Because each participant receives both study products, the comparison follows the same person under different conditions. Randomizing the order helps reduce the risk that an improvement associated with time or treatment sequence is mistaken for a medicine effect.

What participation involves

The university’s recruitment page describes about seven months of participation, including questionnaires, urine testing and a wrist-worn sleep monitor. It seeks adults aged 25 or older with chronic back pain and sleep difficulties, subject to medical screening and approval from their general practitioner.

Eligibility is narrower than simply having a restless night. Other medicines and health conditions can affect suitability, and the researchers must assess those factors before enrollment. Readers interested in participating should use the university’s study contact to confirm current availability and requirements.

The public materials do not give a completely consistent visit schedule: the recruitment page mentions different visit totals in different sections. The registry was last updated in March 2026 and includes an anticipated recruitment endpoint that has passed. Those details make the study team the appropriate source for current logistics; they do not justify assuming that every advertised place remains available.

The registry lists the University of Auckland and the Australian and New Zealand College of Anaesthetists as funding sources. Identifying funding and product supply separately helps readers understand who supports the project and who is responsible for its scientific work.

Safety and consent remain part of the research

The participant information sheet names the University of Auckland as sponsor and Dr. Saad Anis as lead researcher. It describes the study oil as Helius THC10:CBD10 Full Spectrum and explains that the placebo does not contain THC or CBD.

The document emphasizes voluntary participation. Declining to join or withdrawing does not affect normal care, and participation may bring no direct benefit. Its screening requirements cover potentially interacting medicines and conditions that could increase side-effect risks, among other exclusions. This is supervised research, rather than a recommendation to copy a study regimen at home.

Quality standards do not answer the efficacy question

New Zealand’s Ministry of Health distinguishes medicinal cannabis quality verification from medicine approval. Meeting the minimum quality standard concerns product quality and consistency; it does not make a product an approved medicine or establish that it treats a particular condition.

That distinction explains why controlled research still matters even where cannabis products can be prescribed. A standardized product gives investigators something defined to test. It does not supply the answer in advance.

With a target of only 20 participants and a specific patient group, the CPS trial will need to be read within its limits. Any eventual findings will concern the tested formulation, population and study conditions. For now, the news is the effort to build that evidence carefully, with the clinical answer still ahead.

Illustrative stock sleep photograph; the model is not identified as a patient or trial participant. Photo: Los Muertos Crew / Pexels.

Continue Reading

Cannabis

Rubicon’s $3 Million Raise Puts Greenhouse Lighting at the Center of Expansion

The Canadian producer plans to expand output from existing facilities, with a lighting project bringing its combined capacity target forward to June 2027.

Published

on

Potted plants beneath the glass roof of a greenhouse

Rubicon Organics is putting new capital into the lights above an existing crop rather than announcing another cultivation site. The Canadian producer’s October 19 financing announcement outlines a roughly $3 million private placement intended to support lighting and related greenhouse infrastructure at its Pacifica facility in Delta, British Columbia.

The company expects the project to help bring combined annual capacity at Pacifica and its Cascadia facility to 20,000 kilograms by June 2027, about a year earlier than previously anticipated. That is a production target. Whether additional capacity becomes profitable, saleable flower will depend on execution, operating costs and demand.

What the financing is intended to fund

According to Rubicon’s announcement, Siwash Rock Investments subscribed for 6,666,667 common shares at $0.45 each. Proceeds are intended for the lighting project, with the balance going to working capital.

Rubicon says Pacifica’s annual capacity could reach 15,500 kilograms after the upgrade, a 40 percent increase at that facility. The 20,000-kilogram figure refers to both sites together. Those two numbers describe different scopes and should not be added together. Final TSX Venture Exchange acceptance remained outstanding in the announcement.

The operating background behind the project

Rubicon’s second-quarter results, released in August, provide context for the expansion. The company reported net revenue of C$18.5 million, up 23 percent year over year, while adjusted EBITDA fell 18 percent to C$1.1 million. Adjusted EBITDA is the company’s nonstandard earnings measure, not net profit.

Management attributed pressure on profitability to the ramp-up of Cascadia even as revenue grew. It also reported that Pacifica’s per-crop yield metrics had increased approximately 20 percent in the first half of 2026 compared with a year earlier.

Those disclosures show why output and earnings need to be examined separately. A business can sell more while still absorbing the expense of bringing a facility to its intended performance. The lighting investment adds another operational milestone to watch alongside the company’s reported financial results.

The August report put combined capacity at 15,500 kilograms before the planned lighting expansion. That earlier baseline helps clarify the October target: the same figure later describes Pacifica alone, while the combined target rises to 20,000 kilograms.

Why growers pay attention to lighting

There is a research basis for studying how additional light affects cannabis production. A 2022 study in Frontiers in Plant Science tested the THC-dominant cultivar Meridian under different light intensities in an indoor environment. Dry flower weight was higher under the strongest tested photosynthetically active light treatment than under the lowest.

However, the study found no corresponding effect of those intensity treatments on cannabinoid concentrations in the flower. Its ultraviolet treatments also provided no commercially relevant benefit under the tested conditions. More flower and stronger flower were separate questions.

The researchers cautioned that responses vary with genotype and production environment. Their findings explain why light is a serious cultivation variable; they do not independently verify Rubicon’s projected 40 percent increase. A controlled indoor experiment is not a performance test of Pacifica’s greenhouse or its proposed equipment.

The experiment also illustrates why a lighting announcement should identify what success means. In this case, increased dry flower weight did not demonstrate increased flower cannabinoid concentration, even though both measures could matter commercially.

The energy bill belongs in the calculation

A 2021 PLOS ONE study by Utah State University researchers makes another useful distinction. In experiments with medical hemp, the team compared lighting spectra and fixture efficiency. A tested white-and-red LED treatment produced slightly less flower per unit of growing area than a high-pressure sodium treatment, but more flower per dollar of electricity.

The authors concluded that fixture efficacy and upfront cost could matter more to investment returns than spectral distribution at high light levels. Their study also found no effect of spectral quality on CBD or THC concentration under its conditions.

For readers following a greenhouse upgrade, the practical implication is that kilograms alone cannot describe the result. Equipment cost, electricity use and the amount of usable production obtained from that energy all belong in the evaluation. Those research findings are background, not a specification for Rubicon’s project.

For broader demand context, our coverage of Canada’s August retail sales explains why national spending and an individual producer’s performance answer different questions. A market record does not validate a particular expansion forecast.

What will show whether the expansion works

The most useful follow-up will connect construction progress with actual operating results: whether the equipment is installed on time, whether yields improve consistently and whether the additional flower supports sales without eroding margins. Those are checkpoints, rather than outcomes established by the financing.

For cultivators, Rubicon’s plan offers a concrete example of pursuing more output within existing infrastructure. For consumers, the announcement does not guarantee a change in potency, availability or shelf price. The capital has been raised; the production and commercial results still have to follow.

Illustrative stock greenhouse photograph; not Rubicon’s Pacifica facility or a cannabis crop. Photo: Albina White / Pexels.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.